Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial-Reference-Cited by-同舟云学术

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial

Published:2016-01-26 Issue:19 Volume:37 Page:1526-1534
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:Eur Heart J

Author:

Fitchett David,Zinman Bernard,Wanner Christoph,Lachin John M.,Hantel Stefan,Salsali Afshin,Johansen Odd Erik,Woerle Hans J.,Broedl Uli C.,Inzucchi Silvio E.

Funder

Boehringer Ingelheim and Eli Lilly and Company

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/article-pdf/37/19/1526/17356592/ehv728.pdf

Reference28 articles.

1. Heart Failure Prevalence, Incidence, and Mortality in the Elderly With Diabetes

2. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people

3. Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology

4. Intensive glucose control and macrovascular outcomes in type 2 diabetes

5. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

Cited by 817 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empagliflozin-A Sodium Glucose Co-transporter-2 Inhibitor: Overview of its Chemistry, Pharmacology, and Toxicology;Current Diabetes Reviews;2024-10

2. Pure Sensory Thalamic Stroke Presenting As Hemiballismus: A Case Report;Cureus;2024-09-05

3. Effect of ARNI (Sacubitril/Valsartan) and SGLT2 Inhibitors (Dapagliflozin) either alone or in Combination on Heart Failure: An Exploration of Novelty;Journal of Young Pharmacists;2024-08-23

4. SGLT2 inhibition, blood lipids, and cardiovascular disease: A Mendelian randomization study;ESC Heart Failure;2024-07-25

5. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis;The Lancet Diabetes & Endocrinology;2024-07